Lorcaserin Inhibit Glucose-Stimulated Insulin Secretion and Calcium Influx in Murine Pancreatic Islets
Lorcaserin is a serotonergic agonist specific to the 5-hydroxytryptamine 2c receptor (5-HT2CR) that is FDA approved for the long-term management of obesity with or without at least one weight-related comorbidity. Lorcaserin can restrain patients’ appetite and improve insulin sensitivity and hyperins...
Guardado en:
Autores principales: | Muhan Jing, Shanshan Wang, Ding Li, Zeyu Wang, Ziwen Li, Yichen Lu, Tong Sun, Chen Qiu, Fang Chen, Haijuan Yu, Wei Zhang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/adfc739abd40432680c62a204c56bcf9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
por: Hurt RT, et al.
Publicado: (2018) -
Gαi/o-coupled Htr2c in the paraventricular nucleus of the hypothalamus antagonizes the anorectic effect of serotonin agents
por: Eun-Seon Yoo, et al.
Publicado: (2021) -
Structural Basis of Type 2 Secretion System Engagement between the Inner and Outer Bacterial Membranes
por: Iain D. Hay, et al.
Publicado: (2017) -
Diabetic Retinopathy and Insulin Insufficiency: Beta Cell Replacement as a Strategy to Prevent Blindness
por: Eli Ipp
Publicado: (2021) -
Lorcaserin for weight management
por: Taylor JR, et al.
Publicado: (2013)